Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma

Carcinoma, Renal Cell

Kidney Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Bevacizumab

Everolimus

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Sirolimus

Temsirolimus

MTOR Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Immunosuppressive Agents

Immunologic Factors

Study treatment, consisting of bevacizumab + everolimus, was administered as 28-day cycles

Bevacizumab 10 mg/kg administered by IV infusion every 14 days (dose suspension permitted, dose reduction not permitted)

Everolimus 10 mg daily was administered orally (dose reduction to 5 mg daily and then 5 mg every other day, was permitted as needed for toxicity or tolerability)

Dr. Sandy Srinivas

To determine the safety and efficacy of the combination of bevacizumab and everolimus (RAD001) for the treatment of metastatic renal cell cancer

Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)

Progression-free survival (PFS) per RECIST criteria

Number of subjects with objective response (OR)

Number of subjects whose treatment was discontinued due to toxicity

Number of subjects whose treatment was discontinued due to disease progression

Genentech, Inc.

Novartis

Sandy Srinivas

Associate Professor

Bevacizumab + RAD001 (Everolimus)

Study treatment, consisting of bevacizumab + everolimus, was administered as 28-day cycles

Bevacizumab 10 mg/kg administered by IV infusion every 14 days (dose suspension permitted, dose reduction not permitted)

Everolimus 10 mg daily was administered orally (dose reduction to 5 mg daily and then 5 mg every other day, was permitted as needed for toxicity or tolerability)

Everolimus

Bevacizumab

Age, Continuous

Sex: Female, Male

Race (NIH/OMB)

United States

Region of Enrollment

Associate Professor of Medicine (Oncology)

Objective Response (OR)

Objective Response (OR) Duration

Time-to-Treatment Failure (TTF)

Overall Survival (OS)

Number of Subjects With Drug-related SAEs

Total Number of Drug-related SAEs

Treatment Discontinuation Due to Toxicity

Treatment Discontinuation Due to Disease Progression

Progression-free Survival (PFS)

Overall Study

Spots Global Cancer Trial Database for Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial